Clinical Professor of Medicine
Cedars-Sinai Medical Center and UCLA School of Medicine
Stuart Silverman is a Clinical Professor of Medicine at Cedars-Sinai Medical Center and the David Geffen School of Medicine at the University of California in Los Angeles and is Medical Director of the Osteoporosis Medical Center, a nonprofit organization focused on research. He earned his medical degree from Johns Hopkins University Medical School and completed his internship and residency at the University Hospitals in Boston. He remained in Boston for his fellowship at Boston University.
Dr. Silverman is a member of the Council of Scientific Advisors of the International Osteoporosis Foundation, and the American Society for Bone and Mineral Research representative to the National Osteoporosis Foundation Interspecialty Medical Council. He serves on committees in the National Bone Health Alliance and has recently served as one of the three expert clinicians at the Institute for Comparative Effectiveness Research meeting, studying the health benefits of anabolic therapies in osteoporosis. He teaches bone health to rheumatology and endocrinology fellows and residents. Dr. Silverman offers the perspective of a rheumatologist in private practice.
He has participated on editorial boards for journals such as Osteoporosis International, and the Journal of Bone Mineral Research. Dr. Silverman has received both NIH and private funding to study patient preferences, the epidemiology of osteoporotic fractures, the role of bone turnover markers, and activating patients to reduce osteoporosis fracture. He has authored over 210 articles, written several book chapters, and has been invited to speak nationally and internationally on the identification, treatment, and monitoring of patients with osteoporosis.
Dr. Silverman developed the Osteoporosis Assessment Questionnaire (OPAQ), one of the first instruments to measure quality of life in osteoporosis. He was also a member of the World Health Organization task force that developed the Fracture Risk Assessment Tool (FRAX).
Dr. Silverman disclosed the following conflicts of interest for this workshop:
- Speakers bureau: Amgen, Lilly, Radius
- Consultant: Radius, Amgen
- Grant support: Novartis, Amgen, Lilly, Wyeth